Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells

Oncotarget

Volumn 6, Issue 18, 2015, Pages 15752-15771

  Poh, Ashleigh R ^a   O'Donoghue, Robert J J ^a,b   Ernst, Matthias ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

Author keywords

Cancer; Hematopoietic cell kinase; Leukemia; SFK inhibitors; SRC family kinases

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; A 419259; BOSUTINIB; C TERMINAL SRC KINASE; CETUXIMAB; DASATINIB; ERLOTINIB; GEFITINIB; HEMATOPOIETIC CELL KINASE; IMATINIB; IMMUNOTOXIN; INTERLEUKIN 6; ONCOPROTEIN; PROTEIN CBP; PROTEIN PAG; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; RK 20449; SARACATINIB; UNCLASSIFIED DRUG; HCK PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CARCINOMA; CHEMOSENSITIVITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DOWN REGULATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME REPRESSION; ENZYME STRUCTURE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; LUNG CANCER; MELANOMA; METASTASIS; MULTIPLE MYELOMA; NONHUMAN; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL LUNG CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; CELL PROLIFERATION; IMMUNOLOGY; NEOPLASMS; PHYSIOLOGY;

ANIMALS; CELL PROLIFERATION; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-HCK; SIGNAL TRANSDUCTION;

EID: 84937872197     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4199     Document Type: Review

References (201)

1. Lock P, Ralph S, Stanley E, Boulet I, Ramsay R, Dunn A. Two isoforms of murine hck, generated by utilization of alternative translational initiation codons, exhibit different patterns of subcellular localization. Molecular and Cell Biology. 1991; 9:4363-4370.
2. Ziegler SF, Marth JD, Lewis DB, Perlmutter R. Novel protein-tyrosine kinase gene (hck) preferentially expressed in cells of hematopoietic origin. Molecular and Cell Biology. 1987; 7:2276-2285.
3. Robbins S, Quintrell N, Bishop J. Myristoylation and differential palmitoylation of the HCK protein-tyrosine kinases govern their attachment to membranes and association with caveolae. Molecular and Cell Biology. 1995; 15:3507-3515.
4. Stein P, Lee H, Rich S, Soriano P. pp59fyn and mutant mice display differential signaling in thymocytes and peripheral T cells. Cell. 1992; 70:741-750.
5. Straus D, Weiss A. Genetic evidence for the involvement of lck tyrosine kinase in signal transduction through the T-cell antigen receptor. Cell. 1992; 70:585-593.
6. Lowell CA, Soriano P, Varmus HE. Functional overlap in the src gene family: inactivation of hck and fgr impairs natural immunity. Genes and Development. 1994; 8:387-398.
7. Boggon T, Erk M. Structure and regulation of Src family kinases. Oncogene. 2004; 48:7918-7927.
8. Ingley E. Src family kinases: Regulation of their activities, levels and identification of new pathways. BBA. 2007; 1784:56-65.
9. Sicheri F, MoarefiI, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature. 1997; 385:602-609.
10. Guiet R, Poincloux R, Castandet J, Marois L, Labrousse A, Cabec VL, Maridonneau-Parini I. Hematopoietic cell kinase (Hck) isoforms and phagocytic duties -From signaling and actin reorganization to migration and phagocytosis. European Journal of Cell Biology. 2008; 87:527-542.
11. Tintori C, Laurenzana I, Rocca FL, Falci F, Carraro F, Ruiz A, Este JA, Kissova M, Crespan E, Maga G, Biava M, Brullo C, Schenone S, Botta M. Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agents. ChemMedChem. 2012; 8:1353-1360.
12. Roach T, Slater S, Koval M, White L, McFarland E, Okumura M, Thomas M, Brown E. CD45 regulates Src family member kinase activity associated with macrophage integrin-mediated adhesion. Curr Biol. 1997; 7:408-417.
13. Chong Y, Mulhern T, Cheng H. C-terminal Src kinase (CSK) and CSK-homologous (CHK) -endogenous negative regulators of Src-family protein kinases. Growth Factors. 2005; 23:233-244.
14. Chong Y, Mulhern T, Zhu H, Fukita D, Bjorge J, Tantiongco J, Sotirellis N, Lio D, Scholz G, Cheng H. A novel non-catalytic mechanism employed by the C-terminal Src-homologous kinase to inhibit Src-family kinase activity. J Biol Chem. 2004; 279:20752-20766.
15. Ernst M, Gearing D, Dunn A. Functional and biochemical association of Hck with the LIF/IL-6 receptor signal transducing subunit gp130 in embryonic stem cells. EMBO. 1994; 13:1574-1584.
16. Smolinska MJ, Page TH, Urbaniak AM, Mutch BE, Horwood NJ. Hck tyrosine kinase regulates TLR4-induced TNF and IL-6 production via AP-1. The Journal of Immunology. 2011; 187:6043-6051.
17. Pene-Dumitrescu T, Shu S, Wales T, Alvarado J, Shi H, Narute P, Moroco J, Yeh J, Engen J, Smithgall T. HIV-1 Nef interaction influences the ATP-binding site of the Src-family kinase, Hck. BMC Chem Biol. 2012; 12:1-12.
18. MoarefiI, LaFevre-Bernt M, Sicheri F, Huse M, Lee C, Kuriyan J, Miller W. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature. 1997; 650-3.
19. Lowell C, Benton G. Resistance to endotoxic shock and reduced neutrophil migration in mice deficient for the Srcfamily kinases Hck and Fgr. PNAS. 1998; 95:7580-7584.
20. Ernst M, Inglese M, Scholz GM, Harder KW, Clay Fj, Bozinovski S, Waring P, Darwiche R, Kay T, Sly P, Collins R, Turner D, Hibbs ML, Anderson GP, Dunn AR. Constitutive activation of the Src family kinase Hck results in spontaneous pulmonary inflammatory and an enhanced innate immune response. Journal of Experimental Medicine. 2002; 196:589-604.
21. Sirvent A, Benistant C, Roche S. Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am J Cancer Res. 2012; 2:357-371.
22. Miklós Kovács TN, Zoltán Jakus, Cassian Sitaru, Edina Simon, Krisztina Futosi, Bálint Botz, Zsuzsanna Helyes, Clifford A. Lowell, Attila Mócsai. The Src family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without a direct role in leukocyte recruitment. Journal of Experimental Medicine. 2014; 211:1993-2011.
23. Lamagna C, Hu Y, DeFranco A, Lowell C. B cell-specific loss of Lyn kinase leads to autoimmunity. Journal of Immunology. 2014; 192:919-928.
24. Rous P. A transmissible avian neoplasm (sarcoma of the common fowl). J Exp Med. 1910; 12:696-705.
25. Stehelin D, Fujita D, Padgett T, Varmus H, Bishop J. Detection and enumeration of transformation-defective strains of avian sarcoma virus with molecular hybridization. Virology. 1977; 76:675-684.
26. Oppermann H, Levinson A, Varmus H, Levintow L, Bishop J. Uninfected vertebrate cells contain a protein that is closely related to the production of the avian sarcoma virus transforming gene (src). PNAS. 1979; 76:1804-1808.
27. Kiyose S, Nagura K, Tao H, Iagarashi H, Yamada H, Goto M, Maeda M, Kurabe N, Suzuki M, Tsuboi M, Kahyo T, Shinmura K, Hattori N, Sugimura H. Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization. Pathol Int. 2012; 62:477-484.
28. Kubo T, Kuroda Y, Shimizu H, Kokubu A, Okada N, Hosoda F, Arai Y, Nakamura Y, Taniguchi H, Yanagihara K, Imoto I, Inazawa J, Hirohashi S, Shibata T. Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer. Carcinogenesis. 2009; 30:1857-1864.
29. Arcaroli J, Touban B, Tan A, Varella-Garcia M, Powell R, Eckhardt S, Elvin P, Gao D, Messersmith W. Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clin Cancer Res. 2010; 16:4165-4177.
30. Carothers A, Javid S, Moran A, Hunt D, Redston M, Bertagnolli M. Deficient C-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activation and RhoA-dependent actomyosin contractility. Exp Cell Res. 2006; 312:387-400.
31. Majid S, Dar A, Saini S, Arora S, Shahryari V, Zaman M, Chang I, Yamamura S, Tanaka Y, Deng G, Dahiya R. MicroRNA-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Research. 2012; 72:6435-6446.
32. Gregersen L, Jacobsen A, Frankel L, Wen J, Krogh A, Lund A. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One. 2010; 5:e8836.
33. Sen B, Johnson FM. Regulation of src family kinases in human cancers. Journal of Signal Transduction. 2011; 2011:1-14.
34. Mori S, Ronnstrand L, Yokote K, Engstrom A, Courtneidge S, Claesson-Welsh L, Heldin C. Identification of two juxtamembrane autophosphorylation sites in the PDGF betareceptor; involvement in the interaction with Src family tyrosine kinases. EMBO. 1993; 12:2257-2264.
35. Masaki T, Okada M, Tokuda M, Shiratori Y, Hatase O, Shirai M, Nishioka M, Omata M. Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma. Hepatology. 1999; 29:379-384.
36. Benistant C, Bourgaux J, Chapuis H, Mottet N, Roche S, Bali J. The COOH-terminal Src kinase Csk is a tumor antigen in human carcinoma. Cancer Research. 2001; 61:1415-1420.
37. Watanabe N, Matsuda S, Kuramochi S, Tzuku J, Yamamoto T, Endo K. Expression of C-terminal src kinase in human colorectal cancer cell lines. Jpn J Clin Oncol. 1995; 25:5-9.
38. Kawabuchi M, Satomi Y, Takao T, Shimonishi Y, Nada S, Nagai K, Tarakhovsky A, Okada M. Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature. 2000; 404:999-1003.
39. Sirvent A, Benistant C, Pannequin J, Veracini L, Simon V, Bourgaux J, Hollande F, Cruzalegui F, Roche S. Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization. Oncogene. 2010; 29:1303-1315.
40. Jr. Robert Roskoski Src kinase regulation by phosphorylation and dephosphorylation. Biochemical and Biophysical Research Communications. 2005; 331:1-14.
41. Zheng X, Resnick R, Shalloway D. Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi. Int J Cancer. 2008; 122:1999-2007.
42. Zhu S, Bjorge J, Fujita D. PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. Cancer Research. 2007; 67:10129-10137.
43. Shields B, Wiede F, Gurzov E, Wee K, Hauser C, Zhu H, Molloy T, O'Toole S, Daly R, Sutherland R, Mitchell C, McLean C, Tiganis T. TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers. Mol Cell Biol. 2013; 33:557-570.
44. Connelly S, Isley B, Baker C, Gallick G, Summy J. Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells. Mol Carcinog. 2010; 49:1007-1021.
45. Zhang Y, Tu Y, Zhao J, Chen K, Wu C. Reversion-induced LIM interaction with Src reveals a novel Src inactivation cycle. J Cell Biol. 2009; 184:785-792.
46. Bromann B, Korkaya H, Courtneidge S. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene. 2004; 23:7959-7968.
47. Kypta R, Goldberg Y, Ulug E, Courtneidge S. Association between the PDGF receptor and members of the src family of tyrosine kinases. Cell. 1990; 62:481-492.
48. Biscardi J, Ishizawar R, Silva C, Parsons S. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Research. 2000; 2:203-210.
49. Yarom N, Jonker D. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov Med. 2011; 11:95-105.
50. Leroy C, Fialin C, Sirvent A, Simon V, Urbach S, Poncet J, Robert B, Jouin P, Roche S. Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. Cancer Research. 2009; 69:2279-2286.
51. Chatain N, Zieglar P, Fahrenkamp D, Jost E, Moriggl R, Leur HS-Vd, Muller-Newen G. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCL-ABL positive cells. Oncogene. 2013; 32:3587-3597.
52. Clark S, McLaughlin J, Timmons M, Pendergast A, Ben-Neriah Y, Dow L, Crist W, Rovera G, Smith S, Witte O. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science. 1988; 239:775-777.
53. Shtivelman E, Lifshitz B, Gale R, Roe B, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell. 1986; 47:277-284.
54. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE, Skorski T. The Src family kinase Hck couples BCR-ABL to STAT5 activation in myeloid leukemia cells. The EMBO Journal. 2002; 21:5766-5774.
55. Lionberger J, Wilson M, Smithgall T. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is supressed by kinase defective Hck. Journal of Biological Chemistry. 2000; 275:18581-18585.
56. Limbergen HV, Beverloo H, Drunen Ev, Janssens A, Hahlen J, Poppe B, Roy NV, Marynen P, Paepe AD, Slater R, Speleman F. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer. 2001; 30:274-282.
57. Keung Y, Beaty M, Steward W, Jackle B, Pettnati M. Chronic myelocytic leukemia with eosinophilia, t(9;12) (q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature. Genet Cytogenet. 2002; 138:139-142.
58. Hannemann J, McManus D, Kabarowski J, Wiedemann L. Haemopoietic transformation by the TEL/ABL oncogene. Br J Haematol. 1998; 102:475-485.
59. Voss J, Posern G, Hannemann J, Wiedemann L, Turhan A, Poirel H, Bernard O, Adermann K, Kardinal C, Feller S. The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular pathways. Oncogene. 2000; 19:1684-1690.
60. Spiejermann K, Pau M, Schwab R, Schmieja J, Franzrahe S, Hiddemann W. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of haematopoietic precursor cells. Exp Hematol. 2002; 30:262-271.
61. Santos S, Lacronique V, Bouchaert I, Monni R, Bernard O, Gisselbrecht S, Gouilleux F. Constitutive active STAT5 variants induce growth and survival of hematopoietic cells through a PI3-kinase/AKT denepdent pathway. Oncogene. 2001; 20:2080-2090.
62. Pecquet C, Nyga R, Pernard-Lacronique V, Smithgall T, Murakami H, Regnier A, Lassoued K, Gouilleux F. The Src tyrosine kinase Hck is required for Tel-Abl-but not for Tel-Jak2-induced cell transformation. Oncogene. 2007; 26:1577-1585.
63. Sun X, Zhang W, Ramdas L, Stivers DN, Jones DM, Kantarjian HM, Estey EH, Vadhan-Raj S, Medeiros J, Bueso-Ramos CE. Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping. Nature Modern Pathology. 2007; 20:811-820.
64. Hoshino K, Quintas-Cardama A, Yang H, Sanchez-Gonzalez B, Garcia-Manero G. Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chronosome negative acute lymphocytic leukemia. Nature Leukemia. 2007; 21:906-911.
65. Zou D, Yang X, Tan Y, Wang P, Zhu X, Yang W, Kia X, Zhang J, Wang K. Regulation of the hematopoietic cell kinase (HCK) by PML/RARa and PU.1 in acute promyelocytic leukemia. Leukemia Research. 2012; 36:219-223.
66. Liu X-F, Xiang L, Fitzgerald DJ, Pastan I. Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with Src kinase inhibitors. Molecular Cancer Therapeutics. 2014; 13:82-89.
67. Shivakrupa R, Radha V, Sudhakar C, Swarup G. Physical and functional interaction between Hck tyroskine kinase and guanine neucleotide exchange factor C3G results in apoptosis, which is independent of the C3G catalytic domain. Journal of Biological Chemistry. 2003; 278:52188-52194.
68. Podar K, Mostoslavsky G, Sattler M, Tai Y-T, Yatashi T, Catley LP, Hideshima T, Mulligan RC, Chauhan D, Anderson KC. Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in Interleukin 6-induced proliferation and survival of multiple myeloma cells. Journal of Biological Chemistry. 2004; 279:21658-21665.
69. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989; 3:573-581.
70. Hallek M, Neumann C, Schaffer S, Danhauser-Riedl M, Bubnoff Nv, Vos Gd, Druker B, Yasukawa K, Griffin J, Emmerich B. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck and Lyn in multiple myeloma cells. Exp Hematol. 1997; 25:1367-1377.
71. Schaeffer M, Schneiderbauer M, Weidler S, Tavares R, Warmuth M, Vos GD, Hallek M. Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases. Molecular and Cell Biology. 2001; 21:8068-8081.
72. Hausherr A, Tavares R, Schaffer M, Obermeier A, Miksch C, Mitina O, Ellwart J, Hallek M, Krause G. Inhibition of IL-6 dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases. Oncogene. 2007; 26:4987-98.
73. Ernst M, Oates A, Dunn A. gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein kinase pathways. J Biol Chem. 1996; 271:30136-30143.
74. Achim Rody UH, Laos Pusztai, Cornelia Liedtke, Regine Gaetje, Eugen Ruckhaeberle, Christine Solbach, Lars Hanker, Andre Ahr, Dirk Metzler, Knut Engels, Thomas Karn, Manfred Kaufmann. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Research. 2009; 11:1-15.
75. Hanahan D, Weinberg RA. Hallmarks of Cancer: The next generation. Cell. 2011; 144:647-674.
76. Kahlert C, Pecqueux M, Halama N, Dienemann H, Muley T, Pfannschmidt J, Lasitschka F, Klupp F, Schmidt T, Rahbari N, Reissfelder C, Kunz C, Benner A, Falk C, Weitz J, Koch M. Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases. British Journal of Cancer. 2013; 110:441-449.
77. Bettuma IJ, Vasiliauskaitea K, Nygaarda V, Clancya T, Pettersena SJ, Tenstada E, Mælandsmoa GM, Prasmickaitea L. Metastasis-associated protein S100A4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties. Cancer Letters. 2014; 344:28-39.
78. Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Research. 2002; 62:7042-7049.
79. Kitamura T, Kometani K, Hashida H, Matsunaga A, Miyoshi H, Hosogi H, Aoki M, Oshima M, Hattori M, Takabayashi A, Minato N, Taketo M. SMAD-4 deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nature Genetics. 2007; 39:467-475.
80. Vasiljeva O, Papazoglou A, Krüger A, Brodoefel H, Korovin M, Deussing J, Augustin N, Nielsen B, Almholt K, Bogyo M, Peters C, Reinheckel T. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Research. 2006; 66:5242-50.
81. DeNardo D, Barreto J, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens L. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009; 16:91-102.
82. Mitchem JB, Brennan DJ, KnolhoffBL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression and improves chemotherapeutic responses. Cancer Research. 2013; 73:1128-1141.
83. Mitchem J, Brennan D, KnolhoffB, Belt B, Zhu Y, Sanford D, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi G, Gallagher W, Wegner C, West B, Wang-Gillam A, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Research. 2013; 73:1128-1141.
84. Lanskron G, Fuente MDl, Thuwajit P, Thuwajit C, Hermoso M. Chronic inflammation and cytokines in the tumour microenvironment. J Immunol Res. 2014; 2014:1-19.
85. Mishalian I, Bayuh R, Eruslanov E, Michaeli J, Levy L, Zolotarov L, Singhal S, Albelda S, Granot Z, Fridlender Z. Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17-a new mechanism of impaired antitumor immunity. Int J Cancer. 2014; 135:1178-1186.
86. Mohn H, Cabec VL, Fischer S, Maridonneau-Parini I. The src-family protein-tyrosine kinase p59hck is located on the secretory granules in human neutrophils and translocates the phagosome during activation. Biochem J. 1995; 309:657-665.
87. Welch H, Mauran C, Maridonneau-Parini I. Nonreceptor protein-tyrosine kinases in neutrophil activation. Methods. 1996; 9:607-618.
88. Barlic J, Andrews J, Kelvin A, Bosinger S, DeVries M, Xu L, Dobransky T, Felfman R, Ferguson S, Kelvin D. Regulation of tyrosine kinase activation and granule release through beta-arrestin by CXCRI. Nature Immunology. 2000; 1:227-233.
89. Suh H, Kim M, Lee S. Inhibition of granulocyte-macrophage colony-stimulating factor signaling and microglial proliferation by anti-CD45RO: role of Hck tyrosine kinase and phosphatidylinositol 3-kinase/Akt. J Immunol. 2005; 174:2712-2719.
90. Cougoule C, Cabec VL, Poincloux R, Saati TA, Mege J-L, Tabouret G, Lowell CA, Laviolette-Malirat N, Maridonneau-Parini I. Three-dimensional migration of macrophages requires Hck for podosome organization and extracellular matrix-proteolysis. Blood. 2010; 115:1444-1452.
91. English BK, Ihle JN, Myracle A, Yi T. Hck tyroskine kinase activity modulates tumor necrosis factor production by murine macrophages. Journal of Experimental Medicine. 1993; 179:1017-1022.
92. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation and cancer. Cell. 2010; 140:883-899.
93. Popivanova B, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C, Mukaida N. Blocking TNFalpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008; 118:560-570.
94. Wang Y, Wang K, Han G, Wang R, Xiao H, Hou C, Guo R, Dou Y, Shen B, Li Y, Chen G. Neutrophil infiltration favors colitis-associated tumorigenesis by activating the interleukin-1 (IL-1)/IL-6 axis. Mucosal Immunology. 2014; 7:1106-1115.
95. Ning C, Li Y, Y Wang, Han G, Wang R, Xiao H, Li X, Hou C, Ma Y, Sheng D, Shen B, Feng J, Guo R, Li Y and Chen G: Complement activation promotes colitis-associated carcinogenesis through activating intestinal IL-1ß/IL-17A axis. Mucosal Immunology. 2015; Epub ahead of print.
96. Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, Kaibori M, Kamiyama Y, Nishizawa M, Fujisawa J, Okazaki K, Seki T. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology. 2007; 46:48-57.
97. Doll R, Hill B. Smoking and carcinoma of the lung. Br Med J. 1950; 2:739-748.
98. Zins K, Abraham D, Sioud M, Aharinejad S. Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by upregulating the colony-stimulating factor-1 pathway. Cancer Research. 2007; 67:1038-1045.
99. Hou Z, Falcone D, Subbaramaiah K, Danneberg A. Macrophages induce COX-2 expression in breast cancer cells: role of IL-1b autoamplification. Carcinogenesis. 2011; 32:695-702.
100. Smolinska MJ, Horwood NJ, Page TH, Smallie T, Foxwell BMJ. Chemical inhibition of Src family kinases affects major LPS-activated pathways in primary human macrophages. Molecular Immunology. 2008; 45:990-1000.
101. Giagulli C, Ottoboni L, Caveggion E, Rossi B, Lowell C, Constantin G, Laudanna C, Berton G. The Src family kinases Hck and Fgr are dispensible for inside-out, chemoattractant-induced signalling regulating B2 integrin affinity and valency in neutrophils, but are required for B2 integrin-mediated outside-in signaling involved in sustained adhesion. The Journal of Immunology. 2006; 177:604-611.
102. Suen P, LLic D, Caveggion E, Berton G, Damsky C, Lowell C. Impaired integrin-mediated signal transduction, altered cytoskeletal structure and reduced motility in Hck/Fgr deficient macrophages. Journal of Cell Science. 1999; 112:4067-4078.
103. Raviv S, Hawkins KA, DeCamp MM, Kalhan R. Lung cancer in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010; 183:1138-1146.
104. Zhang X, Mahmudi-Azer S, Connett J, Anthonisen N, He J-Q, Pare P, Sandford A. Association of Hck genetic polymorphisms with gene expression and COPD. Hum Gent. 2007; 120:681-690.
105. Ding L, Getz G, Wheeler D, Mardis E, McLellan M, Cibulskis K, Sougnez C, Greulich H, Muzny D, Morgan M, Fulton L, Fulton R, Zhang Q, Wendl M, Lawrence M, Larson D, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455:1069-75.
106. Yanagisawa S, Sugiura H, Yokoyama T, Yamagata T, Ichikawa T, Akamats K, Koarai A, Hirano T, Nakanishi M, Matsunaga K, Minakata Y, Ichinose M. The possible role of hematopoietic cell kinase in the pathophysiology of COPD. Chest. 2009; 135:95-101.
107. Yamaguchi H, Pixley P, Condeelis J. Invadopodia and podosomes in tumor invasion. European Journal of Cell Biology. 2006; 85:213-218.
108. Takenawa T, Suetsugu S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol. 2007; 1:37-48.
109. Park H, Dovas A, Hanna S, Lastrucci C, Coucoule C, Guiet R, Maridonneau-Parini I, Cox D. Tyrosine phosphorylation of Wiskott-Aldrich Syndrome Protein (WASP) by Hck regulates macrophage function. Journal of Biological Chemistry. 2014; 289:7897-7906.
110. Poincloux R, Saati TA, Maridonneau-Parini I, Cabec VL. The oncogenic activity of the Src family kinase Hck requires the coopoerative action of the plasma membrane and lysosome-associated isoforms. European Journal of Cancer. 2009; 45:321-327.
111. Cougoule C, Carréno S, Castandet J, Labrousse A, Astarie-Dequeker C, Poincloux R, Cabec VL, Maridonneau-Parini I. Activation of the lysosome-associated p61Hck isoform triggers the biogenesis of podosomes. Traffic. 2005; 6:682-694.
112. Poincloux R, Vincent C, Labrousse A, Castandet J, Rigo M, Cougoule C, Bordier C, Cabec VL, Maridonneau-Parini I. Re-arrangements of podosome structures are observed when Hck is activated in myeloid cells. European Journal of Cell Biology. 2006; 85:327-332.
113. Guiet R, Goethem EV, Cougoule C, Balor S, Valette A, Saati TA, Lowell CA, Cabec VL, Maridonneau-Parini I. The process of macrophage migration promotes matrix metalloproteinase-independent invasion by tumour cells. The Journal of Immunology. 2011; 187:3806-3814.
114. Tredan O, Galmarini B, Patel K, Tannock I. Drug resistance and the solid tumour microenvironment. J Natl Cancer Inst. 2007; 19:1441-1454.
115. Acharyya A, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris P, Manova-Todorova K, Leversha M, Hogg N, Seshan V, Norton L, Brogi E, Massaque K. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012; 150:165-178.
116. Pastan I, Hassan R, FitzGerald D, Kreitman R. Immunotoxin treatment of cancer. Annu Rev Med. 2007; 25:221-237.
117. Liu Y, Shah K, Yang F, Witucki L, Shokat K. A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Bioorg Med Chem. 1998; 8:1219-1226.
118. Pene-Dumitrescu T, Peterson L, Donato N, Smithgall T. An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broadspectrum Src family kinase inhibitor A-419259. Oncogene. 2008; 27:7055-7069.
119. Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P, Sawyers C. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293:876-880.
120. Kobayashi S, Boggon T, Dayaram T, Jänne P, Kocher O, Meyerson M, Johnson B, Eck M, Tenen D, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New England Journal of Medicine. 2005; 352:786-792.
121. Blencke S, Zech B, Engkvist O, GreffZ, OrfiL, Horváth Z, Kéri G, Ullrich A, Daub H. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chemical Biology. 2004; 5:691-701.
122. Chen Y. Are SRC family kinases responsible for imatiniband dasatinib-resistant chromic myeloid leukemias? Leukemia Research. 2011; 35:27-29.
123. Wheeler D, Lida M, Kruser T, Nechrebecki M, Dunn E, Warmstrong E, Huang S, Harari P. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther. 2009; 8:696-703.
124. Osherov N, Levitzki A. Epidermal-growth-factordependent activation of the src-family kinases. Eur J Biochem. 1994; 225:1047-1053.
125. Kloth M, Laughlin K, Biscardi J, Boerner J, Parsons S. STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor. J Biol Chem. 2003; 278:1671-1679.
126. Montero JC, Seoane S, Ocana A, Pandiella A. Inhibition of Src family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumours. Clinical Cancer Research. 2007; 2011:17.
127. Jallal H, Valentino M, Chen C, Boschelli F, Ali S, Rabbani S. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, grwoth and metastasis in vitro and in vivo. Cancer Research. 2007; 67:1580-1588.
128. Nam H, Im S, Oh D, Elvin P, Kim H, Yook Y, Min A, Song S, Han S, Kim T, Bang Y. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cance. Mol Cancer Ther. 2013; 12:16-26.
129. Serrels A, Macpherson I, Evans T, Lee F, Clark E, Snsom O, Ashton G, Frame M, Brunton V. Identification of potential bio-markers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther. 2006; 5:3014-3022.
130. Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee F, Jove R. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther. 2007; 6:1400-1405.
131. Ferguson J, Arozarena I, Ehrhardt M, Wellbrock C. Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. Oncogene. 2013; 32:86-96.
132. Touny LE, Vieira A, Mendoza A, Khanna C, HoenerhoffM, Green J. Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumour cells. Journal of Clinical Investigation. 2014; 124:156-168.
133. Kopetz S, Lesslie D, Dallas N, Park S, Johnson M, Parikh N, Kim M, Abbruzzese A, Ellis L, Chandra J, Gallick G. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Research. 2009; 69:3842-3849.
134. Maria R. Girotti, Malin Pedersen, Berta Sanchez-Laorden, Amaya Viros, Samra Turajlic, Dan Niculescu-Duvaz, Alfonso Zambon, John Sinclair, Andrew Hayes, Martin Gore, Paul Lorigan, Caroline Springer, James Larkin, Claus Jorgensen, Richard Marais. Inhibiting EGF receptor or Src family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discovery. 2012; 3:158-167.
135. Okamoto W, Okamoto I, Yoshida T, Okamoto K, Takezawa K, Hatashita E, Yamada Y, Kuwata K, Aro T, Yanagihara K, Fukuoka M, Nishio K, Nakagawa K. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition. Mol Cancer Ther. 2010; 9:1188-1197.
136. Haura E, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell M, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28:1387-1394.
137. Johnson F, Bekele B, Feng L, Wistuba I, Tang X, Tran H, Erasmus J, Hwang L, Takebe N, Blumenschein G, Lippman S, Stewert D. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28:4609-4615.
138. Fury M, Baxi S, Shen R, Kelly K, Lipson B, Carlson D, Stambuck H, Haque S, Pfister D. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamos cell carcinoma (HNSCC). Anticancer Res. 2011; 31:249-254.
139. Sharma M, Wrobleski K, Polite B, Knost J, Wallace J, Modi S, Sleckman B, Taber D, Vokes E, Stadler W, Kindler H. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Investigational New Drugs. 2012; 30:1211-1215.
140. Gucalp A, Sparano J, Caravelli J, Santamauro J, Patil S, Abbruzzi A, Pellegrino C, Bromberg J, Dang C, Theodoulou M, Massague J, Norton L, Hudis C, Traina T. Phase II trial of saracatinib (AZD0530), an oral src-inhibitor for the treatment of patients with hormone receptor negative metastatic breast cancer. Clin Breast Cancer. 2011; 11:306-311.
141. Krishnamurty R, Brigham J, Leonard S, Rankitkar P, Larson E, Dale E, Merritt E, Maly D. Active site profiling reveals coupling between domains in SRC-family kinases. Nature Chemical Biology. 2012; 9:43-51.
142. Saito Y, Yuki H, Kuratani M, Hashizume Y, Takagi S, Honma T, Tanaka A, Shirouzu M, Mikuni J, Handa N, Ogahara I, Sone A, Najima Y, Tomabechi Y, Wakiyama M, Uchida N, et al. A Pyrrolo-Pyrimidine Derivative Targets Human Primary AML Stem Cells in Vivo. Science. 2013; 5:1-15.
143. El-Shazly A, Yamaguchi N, Masuyama K, Suda T, Ishikawa T. Novel association of the src family kinases, hck and c-fgr, with CCR3 receptor stimulation: A possible mechanism for eotaxin-induced human eosinophil chemotaxis. Biochemical and Biophysical Research Communications. 1999; 264:163-170.
144. Yoon J, Terada A, Kita H. CD66b regulates adhesion and activation of human eosinophils. J Immunol. 2007; 179:8454-62.
145. Nair K, Zingde S. Adhesion of neutrophils to fibronectin: role of the CD66 antigens. Cell Immunol. 2001; 208:96-106.
146. Marks D, Csar X, Wilson N, Novak U, Ward A, Kanagasundarum V, Hoffman B, Hamilton J. Expression of a Y559F mutant CSF-1 receptor in M1 myeloid cells: A role for Src kinases in CSF-1 receptor mediated differentiation. Mol Cell Biol Res Commun. 1999; 1:144-152.
147. Durden D, Kim H, Liu Y. The Fc gamma RI receptor signals through the activation of hck and MAP kinase. J Immunol. 1995; 154:4039-47.
148. Suzuki T, Kono H, Hirose N, Okada M, Yamamoto T, Yamamoto K, Honda Z. Differential involvement of Src family kinases in Fc gamma receptor-mediated phagocytosis. J Immunol. 2000; 165:473-482.
149. Bosco M, Curiel R, Zea A, Malabarba M, Ortaldo J, Espinoza-Delgado I. IL-2 signalling in human monocytes involves the phosphoryation and activation of p59 hck 1. The Journal of Immunology. 2000; 164:4575-4585.
150. Bohuslav J, Horejsi V, Hansmann C, Stockl J, Weidle U, Majdic O, Bartke I, Knapp W, Stockinger H. Urokinase plasminogen activator receptor, beta 2-integrins, and Srckinases within a single receptor complex of human monocytes. J Exp Med. 1995; 181:1381-1390.
151. Trigwell S, Wood L, Jones P. Soluble urokinase receptor promotes cell adhesion and requires tyrosine-92 for activation of p56/59(hck) Biochemical and Biophysical Research Communications. 2000; 278:440-446.
152. Danhauser-Riedl S, Warmuth M, Druker B, Emmerich B, Hallek M. Activation of Src kinases p53/p56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Research. 1996; 56:3589-3596.
153. Scholz G, Cartledge K, Dunn A. Hck enhances the adherence of lipopolysaccharide-stimulated macrophages via Cbl and phosphatidylinositol 3-kinase. J Biol Chem. 2000; 275:14615-14623.
154. Howlett C, Bisson B, Resek M, Tigley A, Robbins S. The proto-oncogene p120 (Cbl) is a downstream substrate of the Hck protein-tyrosine kinase. Biochemical and Biophysical Research Communications. 1999; 257:129-38.
155. Scott M, Zappacosta F, Kim E, Annan R, Miller W. Identification of novel SH3 domain ligands for the Src family kinase Hck Wiskott-Aldrich syndrome protein (WASP), WASP-interacting protein (WIP) and ELMO1. J Biol Chem. 2002; 277:28238-28246.
156. Yokoyama N, Bakker Cd, Zappacosta F, Huddleston M, Annan R, Ravichandran K, Miller W. Identification of tyrosine residues on ELMO1 that are phosphorylated by the Src-family kinase Hck. Biochemistry. 2005; 44:8841-8849.
157. Baumgartner M, Angelisova P, Setterblad N, Mooney N, Werling D, Horejsi V, Langsley G. Constitutive exclusion of Csk from Hck-positive membrane microdomains permits Src kinase dependent proliferation of Theileria-transformed B-lymphocytes Blood. 2003; 101:1874-1881.
158. Achuthan A, Elsegood C, Msendycz P, Hamilton J, Scholz G. CpG DNA enhances macrophage cell spreading by promoting the Src-family kinase mediated phosphorylation of paxillin. Cell Signal. 2006; 18:2252-2261.
159. Paliwal P, Radha V, Swarup G. Regulation of p73 by Hck through kinase-dependent and independent mechanisms. BMC Mol Biol. 2007; 8:45.
160. Kouroku Y, Soyama A, Fujita E, Urase K, Tsukahara T, Momoi T. RA70 is a src kinase-associated protein expressed ubiquitously. Biochemical and Biophysical Research Communications. 1998; 252:738-742.
161. Poincloux R, Coucoule C, Daubon T, Maridonneau-Parini I, Cabec VL. Tyrosine-phosphorylated STAT5 accumulates on podosomes in Hck-transformed fibroblasts and chronic myeloid leukemia cells. Journal of Cellular Physiology. 2007; 213:212-220.
162. Fumagalli L, Campa C, Germena G, Lowell C, Hirsch E, Berton G. Class I phosphoinositide-3-kinases and SRC kinases play a nonredundant role in regulation of adhesionindependent and -dependent neutrophil reactive oxygen species generation. J Immunol. 2013; 190:3648-60.
163. English B, Orlicek S, Mei Z, Meals E. Bacterial LPS and IFN-gamma trigger the tyrosine phosphorylation of vav in macrophages: evidence for involvement of the hck tyrosine kinase. J Leukoc Biol. 1997; 62:859-864.
164. Pene-Dumitrescu T, Smithgall T. Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinse-dependent manner. Journal of Biological Chemistry. 2010; 285:21446-21457.
165. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Etten RAV, Li S. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nature Genetics. 2004; 36:453-461.
166. Golas J, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli D, Boschelli F. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003; 63:375-381.
167. Hebbard L, Cecena G, Golas J, Sawada J, Ellies L, Charbono A, Williams R, Jimenez R, Wankell M, Arndt K, DeJoy S, Rollins R, Diesl V, Follettie M, Chen L, Control of mammary tumor differentiation by SKI-606 (bosutinib). Oncogene. 2011; 30:301-312.
168. Nguyen T, Hawkins E, Kolluri A, Kmieciak M, Park H, Lin H, Grant S. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinibresistant BCR/ABL(+) leukemia cells. Leuk Res. 2015; 39:65-71.
169. Rabbani S, Valentino M, Arakelian A, Ali S, Boschelli F. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther. 2010; 9:1147-1157.
170. Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, Jove R. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther. 2008; 7:1185-1194.
171. Recaelli S, Boschelli F, Perini P, Pirola A, Viltadi M, Gambacorti-Passerini C. Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib. Leukemia. 2010; 24:1223-1227.
172. Gambacorti-Passerini C, Brümmendorf T, Kim D, Turkina A, Masszi T, Assouline S, Durrant S, Kantarjian H, Khoury H, Zaritskey A, Shen Z, Jin J, Vellenga E, Pasquini R, Mathews V. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol. 2014; 89:732-742.
173. Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillie L, Lang I. Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptorpositive/HER2-negative breast cancer. Oncologist. 2014; 19:346-347.
174. Finn R, Dering J, Ginther C, Wilson C, Glaspy P, Tchekmedyian N, Slamon D. Dasatinib, and orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple negative breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007; 105:319-326.
175. Okamoto W, Okamoto I, Yoshida T, Okamoto K, Takezawa K, Hashita E, Yamada Y, Kuwata K, Arao T, Yanagihara K, Fukuoka M, Nishio K, Nakagawa K. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition. Mol Cancer Ther. 2010; 9:1188-1197.
176. Nagaraj N, Smith J, Revetta F, Washington M, Merchant N. Targeted inhibition of SRC kinase signaling attenuages pancreatic tumourigenesis. Mol Cancer Ther. 2010; 9:2322-2332.
177. Guerrouahen B, Futami M, Vaklavas C, Kanerva J, Whichard Z, Nwawka K, Blanchard E, Lee F, Robinson L, Arceci R, Kornblau S, Wieder E, Cayre Y, Corey S. Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res. 2010; 16:1149-1158.
178. Johnson F, Saigal B, Talpaz M, Donato N. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and nonsmall cell lung caancer cells. Clin Cancer Res. 2005; 11:6924-6932.
179. Shor A, Keschman E, Lee F, Muro-Cacho C, Letson G, Trent J, Pledger W, Jove R. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res. 2007; 67:2800-8.
180. Song Z, Lu P, Furman R, Leonard J, Martin P, Tyrell L, Lee F, Knowles D, Coleman M, Wang Y. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clin Cancer Res. 2010; 16:587-599.
181. Park S, Zhang J, Phillips K, Araujo J, Najjar A, Volgin A, Gelovani J, Kim S, Wang Z, Gallick G. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008; 68:3323-3333.
182. Trevino J, Summy J, Lesslie D, Parikh N, Hong D, Lee F, Donato N, Abbruzzese J, Baker C, Gallick G. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Path. 2006; 168:962-972.
183. Araujo J, Mathew P, Armstrong A, Braud E.L., Posadas E, Lonberg M, Gallick G, Trudel G, Paliwal P, Agrawal S, Logothetis C. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012; 118:63-71.
184. Somlo G, Atzori F, Strauss L, Geese W, Specht J, Gradishar W, Rybicki A, Sy O, Vahdat L, Cortes J. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. Clin Cancer Res. 2013; 19:1884-1893.
185. Fornier M, Morris P, Abbruzzi A, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman A, Sklarin K, Chang J, Norton L, Hudis C. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann Oncol. 2011; 12:2575-2581.
186. Cavalloni G, Peraldo-Neia C, Sarotto I, Gammaitoni L, Migliardi G, Soster M, Marchiò S, Aglietta M, Leone F. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. Mol Cancer Ther. 2012; 11:1528-1538.
187. Nam H, Im S, Oh D, Elvin P, Kim H, Yoon Y, Min A, Song S, Han S, Kim T, Bang Y. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. Mol Cancer Ther. 2013; 12:16-26.
188. Yamaguchi H, Takanashi M, Yoshida N, Ito Y, Kamata R, Fukami K, Yanagihara K, Sakai R. Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors. Cancer Science. 2015; 105:528-536.
189. Dong M, Rice L, Lepler S, Pampo C, Siemann D. Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model. Anticancer Res. 2010; 30:4405-4413.
190. Bai L, Yang J, Ok J, Mack P, Kung H, Evans C. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Int J Cancer. 2012; 130:2693-2702.
191. Luca AD, D'Alessio A, Gallo M, Maiello M, Bode A, Normanno N. Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib. Cell Cycle. 2014; 13:148-156.
192. Gangadhar T, Clark J, Karrison T, Gajewski T. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Investigational New Drugs. 2013; 3:769-793.
193. Laurie S, Goss G, Shepherd F, Reaume M, Nicholas G, Philip L, Wang L, Schock J, Hirsh V, Oza A, Tsao M, Wright J, Leigh N. A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium. Clin Lung Cancer. 2014; 15:52-57.
194. Kaulfuß S, Seemann H, Kampe R, Meyer J, Dressel R, König B, Scharf J, Burfeind P. Blockade of the PDGFR family together with SRC leads to diminished proliferation of colorectal cancer cells. Oncotarget. 2013; 4:1037-1049.
195. Yoon S, Cheong H, Kim S, Kim K, Lee S, Lee N, Park H, Won J. Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line. Cancer Res Treat. 2013; 45:126-133.
196. Nam J, Ino Y, Sakamoto M, Hirohashi S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res. 2002; 8:2430-2436.
197. Ahn J, Lee M. Suppression of autophagy sensitizes multidrug resistant cells towards Src tyrosine kinase specific inhibitor PP2. Cancer Letters. 2011; 310:188-197.
198. Zhang Q, Thomas S, Xi S, Smithgall T, Siegfried J, Kamens J, Gooding W, Grandis J. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res. 2004; 64:6166-6173.
199. Henderson Y, Toro-Serra R, Chen Y, Ryu J, Frederick M, Zhou G, Gallick G, Lai S, Clayman G. Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck. 2014; 36:375-384.
200. Kim S, Kang J, Kim C, Ihm S, Choi M, Yoo H, Lee S. Inhibition of p21 and Akt potentiates SU6656-induced caspase-independent cell death in FRO anaplastic thyroid carcinoma cells. Horm Metab Res. 2013; 45:408-414.
201. Tureckova J, Vojtechova M, Krausova M, Sloncova E, Korinek V. Focal adhesion kinase functions as an akt downstream target in migration of colorectal cancer cells. Transl Oncol. 2009; 2:281-290.